Deepinder Goyal’s Temple acquires Longévous ahead of wearable launch
Temple, Deepinder Goyal’s health-tech venture, has acquired London-based longevity practice Longévous. Its founders will join as chief medical officer and head of science as Temple prepares pre-orders for a limited-edition wearable, with shipping targeted before end-2026.
What happened
Deepinder Goyal’s health-tech venture Temple acquired London-based longevity practice Longévous, adding its founders as chief medical officer and head of
Key facts
- two months
- nearly two decades
- a few thousand units
- before the end of 2026
Why this matters
The deal illustrates how early-stage health-tech entrants can use targeted acquisitions to secure clinical talent, proprietary expertise, and brand trust before launching hardware.
What to watch
- Pre-order pricing, deposit terms, stated markets and any bundled subscription or clinical-service offering.
- Whether Temple markets the wearable as wellness, preventive health or a regulated medical product.
- Clinical validation announcements, sensor specifications and the range of health metrics or interventions promised.
- Further acquisitions or partnerships involving diagnostics, blood testing, telehealth, insurance or AI health coaching.
- Hiring activity for hardware engineering, regulatory affairs, consumer operations and data privacy.
- Any revision to the before-end-2026 shipping target or change from limited edition to wider launch.
- Evidence that Longévous's existing clients, protocols and practitioners are being integrated into a scalable Temple membership model.
- Recruit additional clinicians, data scientists and regulatory leaders around the Longévous team.
- Open pre-orders with a membership, concierge-care or diagnostic-testing bundle rather than a standalone wearable SKU.
- Publish validation studies, biomarker methodology and medical-advisory credentials to establish trust before launch.
- Build partnerships with diagnostic labs, insurers, premium gyms, wellness clinics or corporate-health providers.
- Set up health-data consent, privacy controls and medical-device compliance processes across target launch markets.
- Use the limited edition to collect longitudinal user data and refine the product before a broader commercial rollout.